Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on December 23, 2015, to report amendments to its Amended and Restated Bylaws. The primary change implemented is the adoption of proxy access provisions, allowing eligible stockholders to nominate director candidates for inclusion in the company's proxy materials. This move follows discussions with major stockholders who collectively hold over 37% of Gilead's outstanding stock. The new bylaw allows a stockholder or a group of up to 20 stockholders, owning at least 3% of common stock continuously for three years, to nominate up to 20% of the Board or two directors, whichever is greater. This framework aims to provide meaningful stockholder access while protecting the long-term interests of the company and its shareholders.
Key Highlights
- 1Gilead Sciences amended its Bylaws to implement proxy access.
- 2The amendment allows eligible long-term stockholders to nominate director candidates.
- 3A stockholder or group of up to 20 stockholders, holding 3% of stock for 3 years, can utilize proxy access.
- 4Nominees can constitute up to the greater of 20% of the Board or two directors.
- 5This change was made after consulting with significant stockholders representing over 37% of outstanding stock.
- 6The company aims to balance stockholder access with safeguarding long-term interests and preventing abuse.